GlassScriptPhysician profile
Jacqueline Jones
NPI 1295421170
$1,312.18
in general payments reported to CMS, 2019-2025
22 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $329 · 2024: $558 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $162.54 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $114.01 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $113.90 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $113.65 | 2023-2024 | Otezla, Repatha, Prolia |
| Abbvie INC. | $91.52 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.02 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $72.50 | 2023-2025 | |
| Daiichi Sankyo INC. | $65.94 | 2023-2025 | Injectafer |
| Exact Sciences Corporation | $63.72 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.67 | 2023-2024 | Jardiance |
| Dexcom, INC. | $51.22 | 2023-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.31 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $48.53 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $46.70 | 2024-2025 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $31.75 | 2025 | Zoryve |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $30.09 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $26.46 | 2025 | Auvelity |
| Viatris Specialty LLC | $20.57 | 2025 | Yupelri |
| Ironshore Pharmaceuticals INC. | $20.12 | 2024 | |
| Sumitomo Pharma America, INC. | $18.15 | 2025 | Gemtesa |
| Exeltis, USA INC. | $17.96 | 2023 | Slynd |
| Pfizer INC. | $13.85 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.